VistaGen Therapeutics Inc - Asset Resilience Ratio
VistaGen Therapeutics Inc (VTGN) has an Asset Resilience Ratio of 22.13% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of VistaGen Therapeutics Inc to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how VistaGen Therapeutics Inc's Asset Resilience Ratio has changed over time. See VistaGen Therapeutics Inc net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down VistaGen Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is VistaGen Therapeutics Inc worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $14.40 Million | 22.13% |
| Total Liquid Assets | $14.40 Million | 22.13% |
Asset Resilience Insights
- Good Liquidity Position: VistaGen Therapeutics Inc maintains a healthy 22.13% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
VistaGen Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare VistaGen Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 10.93% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 0.72% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX |
Biotechnology | 87.20% |
|
Tourmaline Bio Inc.
NASDAQ:TRML |
Biotechnology | 77.17% |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230 |
Biotechnology | 16.35% |
Annual Asset Resilience Ratio for VistaGen Therapeutics Inc (2017–2025)
The table below shows the annual Asset Resilience Ratio data for VistaGen Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 15.83% | $13.35 Million | $84.34 Million | -- |
| 2024-03-31 | 0.00% | $0.00 | $123.65 Million | -- |
| 2018-03-31 | 0.00% | $0.00 | $11.28 Million | -- |
| 2017-03-31 | 0.00% | $0.00 | $3.71 Million | -- |
About VistaGen Therapeutics Inc
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an od… Read more